Global Blood Therapeutics, Inc. (GBT): Price and Financial Metrics
GBT Stock Summary
- With a price/sales ratio of 21.84, Global Blood Therapeutics Inc has a higher such ratio than 90.33% of stocks in our set.
- With a year-over-year growth in debt of 56.25%, Global Blood Therapeutics Inc's debt growth rate surpasses 84.38% of about US stocks.
- Revenue growth over the past 12 months for Global Blood Therapeutics Inc comes in at 5,773.01%, a number that bests 99.77% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to Global Blood Therapeutics Inc are SMTC, UTHR, ARLO, QLYS, and LSCC.
- Visit GBT's SEC page to see the company's official filings. To visit the company's web site, go to www.gbt.com.
GBT Stock Price Chart Interactive Chart >
GBT Price/Volume Stats
|Current price||$42.60||52-week high||$83.69|
|Prev. close||$43.50||52-week low||$36.49|
|Day high||$44.65||Avg. volume||1,108,524|
|50-day MA||$47.33||Dividend yield||N/A|
|200-day MA||$56.71||Market Cap||2.63B|
Global Blood Therapeutics, Inc. (GBT) Company Bio
Global Blood Therapeutics is a clinical stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. The company was founded in 2012 and is based in San Francisco, California.
GBT Latest News Stream
|Loading, please wait...|
GBT Latest Social Stream
View Full GBT Social Stream
Latest GBT News From Around the Web
Below are the latest news stories about Global Blood Therapeutics Inc that investors may wish to consider to help them evaluate GBT as an investment opportunity.
RBC Capital Stick to Their Buy Rating for Global Blood Therapeutics
H.C. Wainwright Stick to Their Buy Rating for Global Blood Therapeutics
GBT earnings call for the period ending December 31, 2020.
Global Blood Therapeutics (NASDAQ:GBT) announces its next round of earnings this Wednesday, February 24. Here is Benzinga's everything-that-matters guide for this Wednesday's Q4 earnings announcement. What Are Earnings, Net Income, And Earnings Per Share? Earnings and EPS are useful metrics of profitability. Total earnings also known as net income is equal to total revenue minus total expenses. Dividing net income by the total number of shares outstanding yields EPS. Earnings And Revenue Analysts are predicting Global Blood Therapeutics will report a loss of $0.94 per share on revenue of $39.03 million. In the same quarter last year, Global Blood Therapeutics reported EPS of $1.59 on revenue of $2.11 million. Why Analyst Estimates And Earnings Surprises Are Important Wall Street analyst...
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the following investor conferences: SVB Leerink 10th Annual Global Healthcare Conference on February 26 at 2:20 p.m. ET; andCowen 41st Annual Health Care Conference on March 1 at 11:40 a.m. ET. Ted W. Love, M.D., president and CEO of GBT, will also participate in a virtual panel, Non-Malignant Hematology, at this conference on March 1 at 2:40 p.m. ET. The fireside chats will be webcast live from GBT’s website at www.gbt.com in the Investors section. Replays of the webcasts will be archived and available for one month following each event. About Global Blood Therapeutics Global Blood Therapeutics (GBT) is ...
GBT Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!